Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00782288 · ClinicalTrials.gov registry record · Phase 2

Phase II Study of Digitoxin to Treat Cystic Fibrosis

A Phase 2 study, sponsored by National Jewish Health.

Completed
Registry status
Phase 2
Development phase
24
Enrollment target

NCT00782288: Completed Phase 2 study, sponsored by National Jewish Health.

NCT00782288 is a Phase 2 study that has completed, run by National Jewish Health. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00782288, a Phase 2 study, has completed, sponsored by National Jewish Health.

COMPLETED
Registry status
Phase 2
Development phase
24 participants
Enrollment target

Study Summary

This study will measure the inflammatory effects of digitoxin on IL-8 and neutrophil counts in induced sputum in stable Cystic Fibrosis (CF) patients and the pharmacokinetics of digitoxin in serum. Funding Source-FDA OOPD

Primary Outcome

The Il-8 measurements of sputum digitoxin levels for each group is shown for 5 days (Days 1, 14, 21, 28 and 42).

Interventions

  • OTHER placebo
  • DRUG digitoxin

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2010-08
Est. Completion 2016-08
Phase Phase 2
National Jewish Health

83 total trials

What the finished NCT00782288 record still lists

NCT00782288 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).

The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.

NCT00782288 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00782288 about?

NCT00782288 is a clinical study titled "Phase II Study of Digitoxin to Treat Cystic Fibrosis". This study will measure the inflammatory effects of digitoxin on IL-8 and neutrophil counts in induced sputum in stable Cystic Fibrosis (CF) patients and the pharmacokinetics of digitoxin in serum. Funding Source-FDA OOPD

What is the current status of trial NCT00782288?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2010-08. Estimated completion is 2016-08.

What interventions are being tested in trial NCT00782288?

The interventions under investigation include: placebo (OTHER), digitoxin (DRUG).

Who is sponsoring clinical trial NCT00782288?

This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00782288's enrollment target sits among peer trials

24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00782288, the US trial registry maintained by the National Library of Medicine. NCT00782288 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.